Pharmaron Records Stable Share Capital and Confirms Public Float Compliance in April 2026

Bulletin Express05-06

Pharmaron Beijing Co., Ltd. released its monthly return for the period ended 30 April 2026, reporting no movements in authorised, issued, or treasury shares across its dual-listed share classes.

Key takeaways

1. Authorised share capital • H shares remained at 359.98 million with a par value of RMB 1 each. • A shares stood unchanged at 1.48 billion, also at RMB 1 par. • Combined authorised share capital was RMB 1.84 billion.

2. Issued and treasury shares • Issued H shares (excluding treasury) held steady at 352.71 million, while treasury H shares stayed at 7.26 million—previously repurchased in December 2024 and January 2025 and earmarked for the 2025 H Share Award and Trust Scheme. • Issued A shares were unchanged at 1.48 billion, with no treasury stock.

3. Equity incentive schemes in force • 2022 Restricted A Share Incentive Scheme: up to 0.68 million A shares remain issuable. • 2023 A Share Incentive Scheme: up to 0.91 million A shares remain issuable. • 2025 H Share Award and Trust Scheme: 7.26 million treasury H shares may be granted to employees.

4. Public float The company confirmed compliance with the Main Board’s minimum public-float requirement of 5 % of the issued H-share class (excluding treasury shares).

No share options, warrants, or convertible securities were outstanding or exercised during the month, and no other share capital adjustments occurred. The filing was signed by Company Secretary Mak Po Man Cherie on 6 May 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1110099156?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 17:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110099156","market":"us","top_or_hot":-1,"title":"Pharmaron Records Stable Share Capital and Confirms Public Float Compliance in April 2026","media":"Bulletin Express","content":"<p>Pharmaron Beijing Co., Ltd. released its monthly return for the period ended 30 April 2026, reporting no movements in authorised, issued, or treasury shares across its dual-listed share classes.</p>\n<p>Key takeaways</p>\n<p>1. Authorised share capital  \n• H shares remained at 359.98 million with a par value of RMB 1 each.  \n• A shares stood unchanged at 1.48 billion, also at RMB 1 par.  \n• Combined authorised share capital was RMB 1.84 billion.</p>\n<p>2. Issued and treasury shares  \n• Issued H shares (excluding treasury) held steady at 352.71 million, while treasury H shares stayed at 7.26 million—previously repurchased in December 2024 and January 2025 and earmarked for the 2025 H Share Award and Trust Scheme.  \n• Issued A shares were unchanged at 1.48 billion, with no treasury stock.</p>\n<p>3. Equity incentive schemes in force  \n• 2022 Restricted A Share Incentive Scheme: up to 0.68 million A shares remain issuable.  \n• 2023 A Share Incentive Scheme: up to 0.91 million A shares remain issuable.  \n• 2025 H Share Award and Trust Scheme: 7.26 million treasury H shares may be granted to employees.</p>\n<p>4. Public float  \nThe company confirmed compliance with the Main Board’s minimum public-float requirement of 5 % of the issued H-share class (excluding treasury shares).</p>\n<p>No share options, warrants, or convertible securities were outstanding or exercised during the month, and no other share capital adjustments occurred. The filing was signed by Company Secretary Mak Po Man Cherie on 6 May 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharmaron Records Stable Share Capital and Confirms Public Float Compliance in April 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharmaron Records Stable Share Capital and Confirms Public Float Compliance in April 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-06 17:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pharmaron Beijing Co., Ltd. released its monthly return for the period ended 30 April 2026, reporting no movements in authorised, issued, or treasury shares across its dual-listed share classes.</p>\n<p>Key takeaways</p>\n<p>1. Authorised share capital  \n• H shares remained at 359.98 million with a par value of RMB 1 each.  \n• A shares stood unchanged at 1.48 billion, also at RMB 1 par.  \n• Combined authorised share capital was RMB 1.84 billion.</p>\n<p>2. Issued and treasury shares  \n• Issued H shares (excluding treasury) held steady at 352.71 million, while treasury H shares stayed at 7.26 million—previously repurchased in December 2024 and January 2025 and earmarked for the 2025 H Share Award and Trust Scheme.  \n• Issued A shares were unchanged at 1.48 billion, with no treasury stock.</p>\n<p>3. Equity incentive schemes in force  \n• 2022 Restricted A Share Incentive Scheme: up to 0.68 million A shares remain issuable.  \n• 2023 A Share Incentive Scheme: up to 0.91 million A shares remain issuable.  \n• 2025 H Share Award and Trust Scheme: 7.26 million treasury H shares may be granted to employees.</p>\n<p>4. Public float  \nThe company confirmed compliance with the Main Board’s minimum public-float requirement of 5 % of the issued H-share class (excluding treasury shares).</p>\n<p>No share options, warrants, or convertible securities were outstanding or exercised during the month, and no other share capital adjustments occurred. The filing was signed by Company Secretary Mak Po Man Cherie on 6 May 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1110099156","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110099156","pubTimestamp":1778060575,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Pharmaron Beijing Co., Ltd. released its monthly return for the period ended 30 April 2026, reporting no movements in authorised, issued, or treasury shares across its dual-listed share classes. Key...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"康龙化成2026年4月股本稳定并确认公众持股量合规","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"Pharmaron Beijing Co., Ltd. released its monthly return for the period ended 30 April 2026, reporting no movements in authorised, issued, or treasury shares across its dual-listed share classes.\nKey takeaways\n1. Authorised share capital  \n• H shares remained at 359.98 million with a par value of RMB 1 each.  \n• A shares stood unchanged at 1.48 billion, also at RMB 1 par.  \n• Combined authorised share capital was RMB 1.84 billion.\n2. Issued and treasury shares  \n• Issued H shares (excluding treasury) held steady at 352.71 million, while treasury H shares stayed at 7.26 million—previously repurchased in December 2024 and January 2025 and earmarked for the 2025 H Share Award and Trust Scheme.  \n• Issued A shares were unchanged at 1.48 billion, with no treasury stock.\n3. Equity incentive schemes in force  \n• 2022 Restricted A Share Incentive Scheme: up to 0.68 million A shares remain issuable.  \n• 2023 A Share Incentive Scheme: up to 0.91 million A shares remain issuable.  \n• 2025 H Share Award and Trust Scheme: 7.26 million treasury H shares may be granted to employees.\n4. Public float  \nThe company confirmed compliance with the Main Board’s minimum public-float requirement of 5 % of the issued H-share class (excluding treasury shares).\nNo share options, warrants, or convertible securities were outstanding or exercised during the month, and no other share capital adjustments occurred. The filing was signed by Company Secretary Mak Po Man Cherie on 6 May 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1110099156","isCrawlerRequest":true}